Aurora Cannabis Files Material Change Report

TL;DR

Aurora Cannabis (ACB) filed a material change report, investors need to check what's new.

AI Summary

Aurora Cannabis Inc. filed a Material Change Report on August 7, 2024, as part of its Form 6-K filing with the SEC. This report details significant events affecting the company, though specific financial figures or new business developments are not detailed within the provided text excerpt. The filing indicates Aurora Cannabis Inc. is a foreign private issuer based in Canada.

Why It Matters

This filing signals that Aurora Cannabis Inc. has experienced or is aware of significant events that could impact its business, requiring disclosure to investors.

Risk Assessment

Risk Level: medium — Material Change Reports can indicate significant positive or negative developments, requiring investors to assess the impact on the company's stock.

Key Players & Entities

• Aurora Cannabis Inc. (company) — Filer of the report
• Miguel Martin (person) — Chief Executive Officer and signatory
• 001-38691 (company) — SEC File Number
• 2207 90B St. SW Edmonton, Alberta T6X 1V8 Canada (company) — Principal executive office address

FAQ

From the Filing

0001279569-24-001050.txt : 20240826 0001279569-24-001050.hdr.sgml : 20240826 20240826160636 ACCESSION NUMBER: 0001279569-24-001050 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20240807 FILED AS OF DATE: 20240826 DATE AS OF CHANGE: 20240826 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AURORA CANNABIS INC CENTRAL INDEX KEY: 0001683541 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38691 FILM NUMBER: 241241205 BUSINESS ADDRESS: STREET 1: 2207 90B STREET SW CITY: EDMONTON STATE: A0 ZIP: T6X 1V8 BUSINESS PHONE: 604-362-5207 MAIL ADDRESS: STREET 1: 409 GRANVILLE STREET STREET 2: SUITE 1700 CITY: VANCOUVER STATE: A1 ZIP: V6C 1T2 6-K 1 aurora_6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File No. 001-38691 AURORA CANNABIS INC. (Translation of registrant's name into English) 2207 90B St. SW Edmonton, Alberta T6X 1V8 Canada (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F ☐ Form 40-F ☒ SUBMITTED HEREWITH Exhibits Description 99.1 Material Change Report SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AURORA CANNABIS INC. /s/ Miguel Martin Miguel Martin Chief Executive Officer Date: August 7, 2024 EX-99.1 2 ex991.htm MATERIAL CHANGE REPORT Exhibit 99.1 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 	Name and Address of Company Aurora Cannabis Inc. (“ Aurora ” or the “ Company ”) 2207-90b Street SW Edmonton, Alberta T6X 1V8 Item 2 	Date of Material Change July 31, 2024 Item 3 	News Release A press release describing the material change was disseminated by Aurora before market open on August 1, 2024 through Cision PR Newswire and can be found on SEDAR+ at www.sedarplus.ca. Item 4 	Summary of Material Change The Company announced that it has entered into a commercial collaboration with Cogent International Manufacturing Ltd. (" Cogent "), a wholly-owned subsidiary of Vectura Fertin Pharma Inc. Through this arrangement, Cogent will initially launch its newly developed CBD lozenge on Aurora's Canadian medical cannabis patient platform, giving access to patient feedback which will be used to validate the product proposition and patient responses to the product while building real-world patient data for future analysis. Following the successful launch of the CBD lozenge, the two companies may explore opportunities regarding the potential commercialization of other Vectura Fertin Pharma medical cannabis products in Canada. Item 5 	Full Description of Material Change 5.1 Full Description of Material Change On July 31, 2024, the Company, through a wholly-owned subsidiary, entered into a commercial collaboration with Cogent, a wholly-owned subsidiary of Vectura Fertin Pharma Inc. Through this arrangement, Cogent will initially launch its newly developed CBD lozenge on Aurora's Canadian medical cannabis patient platform, giving access to patient feedback which will be used to validate the product proposition and patient responses to the product while building real-world patient data for future analysis. Following the successful launch of the CBD lozenge, the two companies may explore opportunities regarding the potential commercialization of other Vectura Fertin Pharma medical cannabis products in Canada. The agreement between Aurora and Cogent is expected to have an initial term of 24 mo